お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:慢性閉塞性肺疾患 (COPD) :機会評価、疫学予測、市場力学、パイプライン分析
市場調査レポート
商品コード
769585

慢性閉塞性肺疾患 (COPD) :機会評価、疫学予測、市場力学、パイプライン分析

Chronic Obstructive Pulmonary Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

出版日: | 発行: GervanoRA Data Services LLP | ページ情報: 英文 242 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
慢性閉塞性肺疾患 (COPD) :機会評価、疫学予測、市場力学、パイプライン分析
出版日: 2018年09月15日
発行: GervanoRA Data Services LLP
ページ情報: 英文 242 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の慢性閉塞性肺疾患 (COPD) 治療薬市場について調査分析し、現在・将来の機会に焦点を当てて、市場価値、特許分析、市場シェアなどについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 疾患の概要

  • 疾患の定義と症状
  • 病因と分類
  • 疾患の診断
  • 治療アルゴリズムとガイドライン
  • 疫学と疾病負担
  • 疫学予測

第4章 市場力学

  • 政府規制の動向と影響
  • 価格と償還
  • 取引 (M&A、提携)
  • 新薬の承認 (米国FDA)
  • 新薬の承認 (EMA)
  • 特許分析 (失効、ジェネリック医薬品)

第5章 パイプライン分析

  • パイプライン分析:開発段階別
  • パイプライン分析:地域別
  • パイプライン分析:投与経路別
  • パイプライン分析:薬剤分類別
  • パイプライン分析:作用機序別
  • パイプライン分析:大学・機関別

第6章 承認スケジュールの予測

第7章 慢性閉塞性肺疾患 (COPD) 治療薬の治験サマリー

  • 慢性閉塞性肺疾患 (COPD) 治療薬のパイプライン分析:治験結果別
  • 進行中の治験サマリー
  • 計画中の治験サマリー
  • 最近完了した治験サマリー

第8章 現在・将来の競合情勢

  • 企業
  • 大学・機関

第9章 略語

目次
Product Code: GERPH004

GervanoRA's pipeline analysis and opportunity assessment report "Chronic Obstructive Pulmonary Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018" analyzed and assessed Chronic Obstructive Pulmonary Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chronic Obstructive Pulmonary Disease industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast 2018 - 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT MAJOR FINDINGS
  • 2.2. KEY EVENTS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMPETITIVE SPACE

3. DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION & SYMPTOMS
    • 3.1.1. CLINICAL MANIFESTATIONS
    • 3.1.2. PATHOGENESIS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS

  • 4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
  • 4.2. PRICING AND REIMBURSEMENT
  • 4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
  • 4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
  • 4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
  • 4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHASE 3 MOLECULES
    • 5.1.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHASE 2 MOLECULES
    • 5.1.3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHASE 1 MOLECULES
    • 5.1.4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PRECLINICAL MOLECULES
    • 5.1.5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE EARLY R&D MOLECULES
    • 5.1.6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE INACTIVE AND DISCONTINUED MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES

6. ESTIMATED APPROVAL TIMELINE

    • 6.1.1. METHODOLOGY
    • 6.1.2. ESTIMATED APPROVAL Time lines US & EX-US

7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLINICAL TRIALS SUMMARY

  • 7.1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    • 7.1.1. KEY PHASE 3 RESULTS
    • 7.1.2. KEY PHASE 2 RESULTS
  • 7.2. ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 7.3. PLANNED CLINICAL TRIALS SUMMARY
  • 7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
    • 7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
    • 7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY

8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 8.1. COMPANIES
    • 8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    • 8.1.2. TOP 20 EMERGING COMPANIES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • 8.3. UNIVERSITIES AND INSTITUTES - LICENSING OPPORTUNITIES

9. ABBREVIATIONS

LIST OF TABLES:

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
  • TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 04: MAJOR LICENSING AGREEMENTS IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 07: MAJOR FINANCING DEALS IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 08: MAJOR DEALS IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA RANKED BY DEAL AMOUNT
  • TABLE 09: US FDA APPROVED DRUGS SINCE 2010
  • TABLE 10: EX-US APPROVED DRUGS SINCE 2010
  • TABLE 11: PHASE 3 MOLECULES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE
  • TABLE 12: PHASE 2 MOLECULES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE
  • TABLE 13: PHASE 1 MOLECULES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE
  • TABLE 14: PRECLINICAL MOLECULES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE
  • TABLE 15: EARLY R&D MOLECULES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE
  • TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE
  • TABLE 17: CHRONIC OBSTRUCTIVE PULMONARY DISEASE PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
  • TABLE 18: CHRONIC OBSTRUCTIVE PULMONARY DISEASE PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
  • TABLE 19: CHRONIC OBSTRUCTIVE PULMONARY DISEASE PIPELINE MOLECULES BY UNIVERSITIES
  • TABLE 20: CHRONIC OBSTRUCTIVE PULMONARY DISEASE PIPELINE MOLECULES BY INSTITUTES
  • TABLE 21: ESTIMATED APPROVAL Time lines OF PIPELINE MOLECULES
  • TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
  • TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
  • TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
  • TABLE 25: PLANNED CLINICAL TRIALS FOR THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
  • TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
  • TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
  • TABLE 29: ESTABLISHED COMPANIES SCENARIO
  • TABLE 30: LIST OF EMERGING COMPANIES IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
  • TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES

(Above mentioned Tables are a few among the total 95 Tables in the report)

LIST OF FIGURES:

  • FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
  • FIGURE 02: CHRONIC OBSTRUCTIVE PULMONARY DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
  • FIGURE 03: OVERALL DEALS ACTIVITY IN THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AREA
  • FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
  • FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 06: CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 07: CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 08: CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
  • FIGURE 09: CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 10: CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG PIPELINE ANALYSIS BY DRUG CLASS
  • FIGURE 11 : CHRONIC OBSTRUCTIVE PULMONARY DISEASE PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
  • FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
  • FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
  • FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
  • FIGURE 15: COMPANY FINANCIAL INFORMATION
  • FIGURE 16: COMPANY SWOT ANALYSIS

(Above mentioned Figures are a few among the total 46 Figures in the report)

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.